Physiology and health assessment, risk balance, and model for end-stage liver disease scores: Postoperative outcome of liver transplantation

生理和健康评估、风险平衡以及终末期肝病模型评分:肝移植术后结果

阅读:1

Abstract

BACKGROUND: Liver transplantation aims to increase the survival of patients with end-stage liver diseases and improve their quality of life. The number of organs available for transplantation is lower than the demand. To provide fair organ distribution, predictive mortality scores have been developed. AIM: To compare the Acute Physiology and Chronic Health Evaluation IV (APACHE IV), balance of risk (BAR), and model for end-stage liver disease (MELD) scores as predictors of mortality. METHODS: Retrospective cohort study, which included 283 adult patients in the postoperative period of deceased donor liver transplantation from 2014 to 2018. RESULTS: The transplant recipients were mainly male, with a mean age of 58.1 years. Donors were mostly male, with a mean age of 41.6 years. The median cold ischemia time was 3.1 hours, and the median intensive care unit stay was 5 days. For APACHE IV, a mean of 59.6 was found, BAR 10.7, and MELD 24.2. The 28-day mortality rate was 9.5%, and at 90 days, it was 3.5%. The 28-day mortality prediction for APACHE IV was very good [area under the curve (AUC): 0.85, P < 0.001, 95%CI: 0.76-0.94], P < 0.001, BAR (AUC: 0.70, P < 0.001, 95%CI: 0.58-0.81), and MELD (AUC: 0.66, P < 0.006, 95%CI: 0.55-0.78), P < 0.008. At 90 days, the data for APACHE IV were very good (AUC: 0.80, P < 0.001, 95%CI: 0.71-0.90) and moderate for BAR and MELD, respectively, (AUC: 0.66, P < 0.004, 95%CI: 0.55-0.77), (AUC: 0.62, P < 0.026, 95%CI: 0.51-0.72). All showed good discrimination between deaths and survivors. As for the best value for liver transplantation, it was significant only for APACHE IV (P < 0.001). CONCLUSION: The APACHE IV assessment score was more accurate than BAR and MELD in predicting mortality in deceased donor liver transplant recipients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。